GIST Cancer UK News


Please see the latest news, research and findings below...

GIST Support UK attends Cancer52 parliamentary reception – May 2016

On 20th April Nic Puntis (Chair GSUK) & Jayne Bressington (Vice Chair GSUK / Patient Director PAWS-GIST, pictured left) went to Westminster and attended a parliamentary reception organised by Cancer52, a coalition of more than 80 charities representing rare and less common cancers. The reception was hosted and addressed by Chairman of the All-Party Parliamentary Group on Cancer […]

Continue reading

GSUK Research Update – April 2016

In 2012 GIST Support UK granted £20,000 funding to Professor Ian Judson and his team at the Royal Marsden for a research project. This project aimed to collect tissue samples stored in hospital pathology departments for GIST patients who had been treated at the Marsden over previous years and then to retrospectively undertake mutational analysis of […]

Continue reading

#100,000voices e-petition delivered to No. 10 Downing Street – 23 June 2015

Sincere thanks to everyone who has supported us with the call to retain regorafenib on the Cancer Drugs fund for GIST patients. Yesterday was our appointment with No. 10 Downing Street to deliver our #100,000voices e-petition containing 103,841 signatures supporting retention of regorafenib for GIST patients in England. We were joined by MP’s representing constituents […]

Continue reading

Regorafenib is now officially back on the cancer drugs fund for GIST patients in England – 2015

23rd May 2015 – We are absolutely delighted to report that Regorafenib is now officially back on the cancer drugs fund for GIST patients in England. This is fantastic news and we would like to thank everyone who contributed to this decision: our fantastic #100,000voices team including William Bassett and the team at TMW. our Clinicians […]

Continue reading

regorafenib (Stivarga®) is accepted for use within NHS Scotland – 2015

regorafenib has been approved in Scotland for treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST) who have progressed on or are intolerant to prior treatment with imatinib and sunitinib. This advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of regorafenib and is contingent […]

Continue reading